Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 19Myelodysplastic Syndromes 7Leukemia, Hairy Cell 4Leukemia, Biphenotypic, Acute 4Recurrence 3Leukemia 3Sarcoma, Myeloid 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Monocytic, Acute 2Blast Crisis 2Targeted Therapy 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myasthenia Gravis 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

ruxolitinib 3venetoclax 2fludarabine phosphate 2duvelisib 2thymoglobulin 1romidepsin 1itacitinib 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Lisaftoclax 1Depsipeptides 1Cyclosporins 1Cyclosporine 1Cladribine 1Busulfan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × Cladribine × 1 year × Clear all
NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡